These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 24270265)

  • 1. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
    Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
    Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.
    Aghamohammadzadeh R; Zhang YY; Stephens TE; Arons E; Zaman P; Polach KJ; Matar M; Yung LM; Yu PB; Bowman FP; Opotowsky AR; Waxman AB; Loscalzo J; Leopold JA; Maron BA
    FASEB J; 2016 Jul; 30(7):2511-27. PubMed ID: 27006450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
    Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
    Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.
    Krymskaya VP; Snow J; Cesarone G; Khavin I; Goncharov DA; Lim PN; Veasey SC; Ihida-Stansbury K; Jones PL; Goncharova EA
    FASEB J; 2011 Jun; 25(6):1922-33. PubMed ID: 21368105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.
    Kudryashova TV; Goncharov DA; Pena A; Kelly N; Vanderpool R; Baust J; Kobir A; Shufesky W; Mora AL; Morelli AE; Zhao J; Ihida-Stansbury K; Chang B; DeLisser H; Tuder RM; Kawut SM; Silljé HH; Shapiro S; Zhao Y; Goncharova EA
    Am J Respir Crit Care Med; 2016 Oct; 194(7):866-877. PubMed ID: 27119551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.
    He Y; Zuo C; Jia D; Bai P; Kong D; Chen D; Liu G; Li J; Wang Y; Chen G; Yan S; Xiao B; Zhang J; Piao L; Li Y; Deng Y; Li B; Roux PP; Andreasson KI; Breyer RM; Su Y; Wang J; Lyu A; Shen Y; Yu Y
    Am J Respir Crit Care Med; 2020 May; 201(10):1263-1276. PubMed ID: 31917615
    [No Abstract]   [Full Text] [Related]  

  • 7. Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells.
    Abeyrathna P; Kovacs L; Han W; Su Y
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C24-34. PubMed ID: 27099352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.
    Houssaini A; Abid S; Derumeaux G; Wan F; Parpaleix A; Rideau D; Marcos E; Kebe K; Czibik G; Sawaki D; Treins C; Dubois-Randé JL; Li Z; Amsellem V; Lipskaia L; Pende M; Adnot S
    Am J Respir Cell Mol Biol; 2016 Sep; 55(3):352-67. PubMed ID: 26991739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
    Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
    Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.
    Wang AP; Li XH; Yang YM; Li WQ; Zhang W; Hu CP; Zhang Z; Li YJ
    PLoS One; 2015; 10(6):e0130806. PubMed ID: 26120832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension.
    Kudryashova TV; Goncharov DA; Pena A; Ihida-Stansbury K; DeLisser H; Kawut SM; Goncharova EA
    Pulm Circ; 2015 Dec; 5(4):667-80. PubMed ID: 26697174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.
    Kudryashova TV; Dabral S; Nayakanti S; Ray A; Goncharov DA; Avolio T; Shen Y; Rode A; Pena A; Jiang L; Lin D; Baust J; Bachman TN; Graumann J; Ruppert C; Guenther A; Schmoranzer M; Grobs Y; Eve Lemay S; Tremblay E; Breuils-Bonnet S; Boucherat O; Mora AL; DeLisser H; Zhao J; Zhao Y; Bonnet S; Seeger W; Pullamsetti SS; Goncharova EA
    Circ Res; 2022 Mar; 130(5):760-778. PubMed ID: 35124974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
    Houssaini A; Abid S; Mouraret N; Wan F; Rideau D; Saker M; Marcos E; Tissot CM; Dubois-Randé JL; Amsellem V; Adnot S
    Am J Respir Cell Mol Biol; 2013 May; 48(5):568-77. PubMed ID: 23470622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
    Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
    PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertension.
    Zhuang W; Lian G; Huang B; Du A; Gong J; Xiao G; Xu C; Wang H; Xie L
    Mol Cell Biochem; 2019 May; 455(1-2):169-183. PubMed ID: 30511343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.